The DOI matches its Crossref record; 323 of the 323 references it cites were found in a registry or an index.
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–323 of 323
The Dosing of Atypical Antipsychotics
de León, J., Armstrong, S. C., & Cozza, K. L. (2005) · Psychosomatics · doi:10.1176/appi.psy.46.3.262 · Cited by 124
COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence.
Müller, N. (2010) · PubMed · Cited by 122
Defining and Measuring Clinical Effectiveness in the Treatment of Schizophrenia
Nasrallah, H. A., Targum, S. D., Tandon, R., McCombs, J. S., & ROSS, R. W. (2005) · Psychiatric Services · doi:10.1176/appi.ps.56.3.273 · Cited by 121
Self-citationTREATMENT OF SCHIZOPHRENIC REACTIONS WITH PHENOTHIAZINE DERIVATIVES
Casey, J. F., Lasky, J. J., Klett, C. J., & Hollister, L. E. (1960) · American Journal of Psychiatry · doi:10.1176/ajp.117.2.97 · Cited by 115
Oil and Water or Oil and Vinegar? Evidence-Based Medicine Meets Recovery
Davidson, L., Drake, R. E., Schmutte, T. J., Dinzeo, T. J., & Andrés-Hyman, R. C. (2009) · Community Mental Health Journal · doi:10.1007/s10597-009-9228-1 · Cited by 113
Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors
Aloyo, V. J., Berg, K. A., Spampinato, U., Clarke, W. P., & Harvey, J. A. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.10.010 · Cited by 112
Binder, M. D., Correll, C. U., & Cohen, D. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.12.029 · Cited by 112
Early intervention in patients at ultra high risk of psychosis: benefits and risks
de Koning, M. B., Bloemen, O., van Amelsvoort, T., Becker, H. E., Nieman, D. H., van der Gaag, M., & Linszen, D. H. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01372.x · Cited by 111
Phenothiazines and structurally related drugs
Drugs, S. R., Forrest, I. S., Carr, C. J., et al. (1974) · Raven Press eBooks · Cited by 110
Chlorpromazine Dose for People With Schizophrenia
de Haan, S., & Liu, X. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp014 · Cited by 109
Pharmacogenetics in Psychiatry: Are We Ready for Widespread Clinical Use?
Arranz, M. J., & Kapur, S. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn114 · Cited by 107
Rationale for the study of early intervention
Wyatt, R. J., & Henter, I. D. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00242-0 · Cited by 106
Pharmacological Cognitive Enhancement in Schizophrenia
Harvey, P. D. (2009) · Neuropsychology Review · doi:10.1007/s11065-009-9103-4 · Cited by 106
The spurious advance of antipsychotic drug therapy
Tyrer, P. J., & Kendall, T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61765-1 · Cited by 106
Early detection and intervention of psychosis. A review
Salokangas, R. K. R., & McGlashan, T. H. (2008) · Nordic Journal of Psychiatry · doi:10.1080/08039480801984008 · Cited by 105
The prevention of schizophrenia
Yung, A. R., Killackey, E., Hetrick, S. E., Parker, A. G., Schultze-Lutter, F., Klosterkoetter, J., Purcell, R., & Mcgorry, P. D. (2007) · International Review of Psychiatry · doi:10.1080/09540260701797803 · Cited by 104
Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications
Gaspar, P. A., Bustamante, M. L., Hernán Silva, I., & Aboitiz, F. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06325.x · Cited by 102
Behavioral Indices in Antipsychotic Drug Discovery
Porsolt, R. D., Moser, P. C., & Castagné, V. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166710 · Cited by 102
&, C. B. F., & Lerner, R. M. (2005) · Encyclopedia of Applied Developmental Science · doi:10.4135/9781412950565.n118 · Cited by 100
The Role of Phosphodiesterases in Schizophrenia: Therapeutic Implications
Siuciak, J. A. (2008) · CNS Drugs · doi:10.2165/0023210-200822120-00002 · Cited by 100
Blood Dyscrasias Induced by Psychotropic Drugs
(2004) · Pharmacopsychiatry · doi:10.1055/s-2004-815513 · Cited by 100
Strategies for Maximizing Clinical Effectiveness in the Treatment of Schizophrenia
Tandon, R., Targum, S. D., Nasrallah, H. A., & ROSS, R. W. (2006) · Journal of Psychiatric Practice · doi:10.1097/00131746-200611000-00003 · Cited by 98
Self-citationGlycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification.
Javitt, D. C. (2009) · PubMed · Cited by 96
Haydar, S. N., & Dunlop, J. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790410983 · Cited by 93
Malmberg, L., Fenton, M., & Rathbone, J. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001360 · Cited by 91
The Combined Use of Electroconvulsive Therapy and Antipsychotics in Patients With Schizophrenia
Braga, R. J., & Petrides, G. (2005) · Journal of Ect · doi:10.1097/01.yct.0000165500.60784.05 · Cited by 91
Antidepressants for the treatment of depression in people with schizophrenia: a systematic review
WHITEHEAD, C., Moss, S., Cardno, A. G., & Lewis, G. (2003) · Psychological Medicine · doi:10.1017/s0033291703007645 · Cited by 91
Girón, M., Fernández-Yañez, A., Mañá-Alvarenga, S., Molina-Habas, A., Nolasco, A., & Gómez-Beneyto, M. (2010) · Psychological Medicine · doi:10.1017/s0033291709006126 · Cited by 89 · cited 1×
“Meta-analyses suggest that these interventions reduce high expressed emotion among relatives, and decrease relapse and rehospitalization rates (Brown et al., 1972; Mari and Streiner, 1994; Pitschel-Walz et al., 2001; Pilling et al., 2002a; Giron et al., 2010).”
BackgroundThe future (or lack of future) of personalized prescription in psychiatry
de León, J. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.10.002 · Cited by 89
Cognitive remediation for schizophrenia: it is even more complicated
Wykes, T., & Huddy, V. C. (2009) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328322fbf4 · Cited by 86
Kim, D. H., Maneen, M. J., & Stahl, S. M. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.020 · Cited by 85
Neurocognitive Impairment in Schizophrenia and how it Affects Treatment Options
Bilder, R. M. (1997) · The Canadian Journal of Psychiatry · doi:10.1177/070674379704200303 · Cited by 85
Effectiveness of second generation antipsychotics: A systematic review of randomized trials
Johnsen, E., & Jørgensen, H. A. (2008) · BMC Psychiatry · doi:10.1186/1471-244x-8-31 · Cited by 83
Progress in Defining Optimal Treatment Outcome in Schizophrenia
Remington, G. J., Foussias, G., & Agid, O. (2009) · CNS Drugs · doi:10.2165/11530250-000000000-00000 · Cited by 82
Antipsychotic Drugs for First-Episode Schizophrenia: A Comparative Review
Salimi, K., Jarskog, L. F., & Lieberman, J. A. (2009) · CNS Drugs · doi:10.2165/11314280-000000000-00000 · Cited by 82
Thirthalli, J., Venkatesh, B. K., Kishorekumar, K. V., Arunachala, U., Venkatasubramanian, G., Subbakrishna, D. K., & Gangadhar, B. N. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01299.x · Cited by 81
Early intervention in psychotic disorders: faith before facts?
Bosanac, P., Patton, G. C., & Castle, D. J. (2009) · Psychological Medicine · doi:10.1017/s0033291709990341 · Cited by 81
5-HT6 Receptor Antagonists as Potential Therapeutics for Cognitive Impairment
Rossé, G., & Schaffhauser, H. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790411036 · Cited by 80
Green, M. F., & BRAFF, D. L. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01027-1 · Cited by 79
Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists
Roser, P., Vollenweider, F. X., & Kawohl, W. (2008) · The World Journal of Biological Psychiatry · doi:10.3109/15622970801908047 · Cited by 78
Roussos, P., Giakoumaki, S. G., & Bitsios, P. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.07.008 · Cited by 77
Krystal, J. H., Tolin, D. F., Sanacora, G., Castner, S. A., Williams, G. V., Aikins, D. E., Hoffman, R. E., & D'Souza, D. C. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.05.002 · Cited by 76
Antipsychotics in early onset Schizophrenia: Systematic review and meta-analysis
Armenteros, J. L., & Davies, M. (2006) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-005-0515-2 · Cited by 75
Trajectories and Antecedents of Treatment Response Over Time in Early-Episode Psychosis
Levine, S. Z., & Rabinowitz, J. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn120 · Cited by 75
Systematic Overview of Cochrane Reviews for Anticholinergic Effects of Antipsychotic Drugs
Ozbilen, M., & Adams, C. E. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31819a91f1 · Cited by 74
Antipsychotic-Like Properties of 5-α-Reductase Inhibitors
Bortolato, M., Frau, R., Orrù, M., Bourov, Y., Marrosu, F., Mereu, G., Devoto, P., & Gessa, G. L. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.39 · Cited by 74
Meta-analyses of randomized controlled trials of social skills training and cognitive remediation.
Krabbendam, L., & Alemán, A. (2003) · PubMed · Cited by 74
Lesage, A., & Steckler, T. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.043 · Cited by 73
Haloperidol dose for the acute phase of schizophrenia
Donnelly, L., Rathbone, J., & Adams, C. E. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001951.pub2 · Cited by 71
Life skills programmes for chronic mental illnesses
Tungpunkom, P., & Nicol, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000381.pub2 · Cited by 70
Bradley, S. R., Lameh, J., Ohrmund, L., Son, T., Bajpai, A., Nguyen, D., Friberg, M., Burstein, E. S., Spalding, T. A., Ott, T. R., et al. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.10.003 · Cited by 68
Zisook, S., Kasckow, J., Golshan, S., Fellows, I. E., Solorzano, E., Lehman, D., Mohamed, S., & Jeste, D. V. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04261 · Cited by 67
Basan, A., Kissling, W., & Leucht, S. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.01.016 · Cited by 66
Neves, G. A., Menegatti, R., Antonio, C. B., Grazziotin, L. R., Vieira, R. O., Rates, S. M. K., Noël, F., Barreiro, E. J., & Fraga, C. A. M. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.01.040 · Cited by 64
Painuly, N., & Chakrabarti, S. (2006) · Journal of Ect · doi:10.1097/00124509-200603000-00013 · Cited by 62
Wobrock, T., & Soyka, M. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.02.008 · Cited by 62
Leucht, S., Kissling, W., & McGrath, J. J. (2004) · PubMed · Cited by 60
Waghorn, G., Chant, D. C., White, P., & Whiteford, H. (2004) · Acta Psychiatrica Scandinavica · doi:10.1046/j.1600-0447.2003.00269.x · Cited by 60
Dose Response and Atypical Antipsychotics in Schizophrenia
Kinon, B. J., AHL, J. S. B., Stauffer, V. L., Hill, A. L., & Buckley, P. F. (2004) · CNS Drugs · doi:10.2165/00023210-200418090-00005 · Cited by 59
Antipsychotic Drug Treatment in First-Episode Psychosis
Derks, E. M., Fleischhacker, W. W., Boter, H., Peuskens, J., & Kahn, R. S. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181d2193c · Cited by 59
Hugenholtz, G. W. K., Heerdink, E. R., Stolker, J. J., Meijer, W. E. E., Egberts, T. C. G., & Nolen, W. A. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0606 · Cited by 59
Kane, J. M. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.8.1316 · Cited by 58
Considering schizophrenia from a prevention perspective
Compton, M. T. (2004) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2003.10.003 · Cited by 58
The action of neuroleptic drugs
Haase, H. J., & Janssen, P. A. J. (1985) · Elsevier eBooks · Cited by 57
Review Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia?
DeQuardo, J. R., & Tandon, R. (1998) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(98)00024-7 · Cited by 57
Self-citationMatheson, S. L., Green, M. J., Loo, C. K. A., & Carr, V. J. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.01.002 · Cited by 57
Schizophrenia endophenotypes as treatment targets
Thaker, G. K. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.9.1189 · Cited by 57
Shared Decision Making in Antipsychotic Management
Mistler, L. A., & Drake, R. E. (2008) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000341889.97759.54 · Cited by 56
The Promise and Reality of Pharmacogenetics in Psychiatry
Zandi, P. P., & Judy, J. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.12.001 · Cited by 56
Emerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era
Marino, M. J., Knutsen, L. J. S., & Williams, M. R. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701094q · Cited by 56
Typical and Atypical Antipsychotics – The Misleading Dichotomy
Fischer-Barnicol, D., Lanquillon, S., Haen, E., Zöfel, P., Koch, H. J., Dose, M., & Klein, H. E. (2008) · Neuropsychobiology · doi:10.1159/000135641 · Cited by 55
Lithium for Schizophrenia Revisited
Leucht, S., Kissling, W., & McGrath, J. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0206 · Cited by 55
The American Psychiatric Press Textbook of Psychopharmacology
Dünner, D. L. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.8.1228-a · Cited by 54
Pregnenolone, Dehydroepiandrosterone, and Schizophrenia: Alterations and Clinical Trials
Ritsner, M. S. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00118.x · Cited by 54
Lambert, M., Schimmelmann, B., Naber, D., Eich, F. X., Schulz, H., Huber, C. G., & Karow, A. (2009) · Pharmacopsychiatry · doi:10.1055/s-0029-1234105 · Cited by 53
Management of Patients Presenting with Acute Psychotic Episodes of Schizophrenia
Thomas, P., Alptekın, K., Gheorghe, M., Mauri, M., Olivares, J. M., & Riedel, M. J. (2009) · CNS Drugs · doi:10.2165/00023210-200923030-00002 · Cited by 51
Yang, S.-Y., Yang, Y.-H. K., Chong, M.-Y., Yang, Y.-H., Chang, W.-H., & Lai, C.-S. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100069 · Cited by 50
Heterogeneity of Treatment Effects in Schizophrenia
Stroup, T. S. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.02.005 · Cited by 43
Epigenetic Therapeutic Strategies for the Treatment of Neuropsychiatric Disorders
Deutsch, S. I., Rosse, R. B., Mastropaolo, J. P., Long, K. D., & Gaskins, B. L. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318067e255 · Cited by 42
Ran, M., Chan, C., Chen, E. Y. H., Mao, W.-J., Hu, S., Tang, C., Lin, F.-R., & Conwell, Y. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.108.055301 · Cited by 42
The impact of pharmacogenetics on the development and use of antipsychotic drugs
Reynolds, G. P. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.07.018 · Cited by 41
Carbamazepine Augmentation for Schizophrenia
Leucht, S., McGrath, J. J., White, P., & Kissling, W. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0308 · Cited by 40
Thirthalli, J., Venkatesh, B. K., Naveen, M. N., Venkatasubramanian, G., Arunachala, U., Kumar, K. K., & Gangadhar, B. N. (2010) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.58893 · Cited by 38
Tandon, R., Ribeiro, S. C. M., DeQuardo, J. R., GOLDMAN, R. S., Goodson, J. A., & Greden, J. F. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90242-6 · Cited by 38
Self-citationComparing Acute Toxicity of First- and Second-Generation Antipsychotic Drugs
Ciranni, M. A., Kearney, T. E., & Olson, K. R. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04315 · Cited by 37
Sherwood, M., Thornton, A. E., & Honer, W. G. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005961 · Cited by 36
The intersection of pharmacology, imaging, and genetics in the development of personalized medicine
Gerretsen, P., Müller, D. J., Tiwari, A. K., Mamo, D. C., & Pollock, B. G. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.4/pgerretsen · Cited by 35
Thirthalli, J., Phutane, V. H., Muralidharan, K., Kumar, C. N., Munishwar, B., Baspure, P., & Gangadhar, B. N. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970902718782 · Cited by 35
The importance of dosage in antipsychotic drug administration ? A review of dose-response studies
Gárdos, G., Cole, J. O., & Orzack, M. H. (1973) · Psychopharmacology · doi:10.1007/bf00414036 · Cited by 35
Geffen, Y., Nudelman, A., Gil‐Ad, I., Rephaeli, A., Huang, M., Savitsky, K., Klapper, L. N., Winkler, I., Meltzer, H. Y., & Weizman, A. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.07.002 · Cited by 35
Is it time to trial vitamin D supplements for the prevention of schizophrenia?
McGrath, J. J. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01551.x · Cited by 34
Indicators of Conformance With Guidelines of Schizophrenia Treatment in Mental Health Services
Bollini, P., Pampallona, S., Nieddu, S., Bianco, M., Tibaldi, G., & Munizza, C. (2008) · Psychiatric Services · doi:10.1176/appi.ps.59.7.782 · Cited by 33
Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia
Gäebel, W., & Riesbeck, M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.06.016 · Cited by 30
Combination Therapy in the Treatment of Schizophrenia
Wolff‐Menzler, C., Hasan, A., Malchow, B., Falkai, P., & Wobrock, T. (2010) · Pharmacopsychiatry · doi:10.1055/s-0030-1249097 · Cited by 29
Therapeutic Utility of NK3 Receptor Antagonists for the Treatment of Schizophrenia
Dawson, L. A., & Smith, P. W. (2009) · Current Pharmaceutical Design · doi:10.2174/138161210790170067 · Cited by 29
Kozikowski, A. P., Cho, S. J., Jensen, N. H., Allen, J. A., Svennebring, A. M., & Roth, B. L. (2010) · ChemMedChem · doi:10.1002/cmdc.201000186 · Cited by 28
Intervention in the at-risk state to prevent transition to psychosis
Ruhrmann, S., Schultze‐Lutter, F., & Klosterkötter, J. (2009) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328324b687 · Cited by 28
Repetitive transcranial magnetic stimulation for refractory symptoms in schizophrenia
Blumberger, D. M., Fitzgerald, P. B., Mulsant, B. H., & Daskalakis, Z. J. (2010) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3283366657 · Cited by 28
Cardiovascular disease and diabetes in people with severe mental illness
Binder, M. D., Dekker, J. M., Wood, D., Kahl, K. G., & Möller, H. (2009) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/s2173-5050(09)70031-7 · Cited by 27
Treating Schizophrenia: Novel Targets for the Cholinergic System
Money, T., Scarr, E., Udawela, M., Gibbons, A. S., Jeon, W. J., Seo, M. S., & Dean, B. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012062 · Cited by 26
The Concept of Population Prevention: Application to Schizophrenia
Mojtabai, R., Malaspina, D., & Susser, E. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007047 · Cited by 26
Kanuma, K., Aoki, T., & Shimazaki, Y. (2009) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488910789753512 · Cited by 23
Novel consortium to address shortfall in innovative medicines for psychiatric disorders
Hughes, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2939 · Cited by 23
Blanc, O., Brousse, G., Méary, A., Leboyer, M., & Llorca, P. (2009) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2009.00751.x · Cited by 23
Maintenance antipsychotic drugs do prevent relapse: A reply to Tobias and MacDonald.
Davis, J. M., Gosenfeld, L. F., & Tsai, C. C. (1976) · Psychological Bulletin · doi:10.1037/0033-2909.83.3.431 · Cited by 22
Treatment of schizophrenia in the 21st Century: beyond the neurotransmitter hypothesis
Rogers, D. P., & Goldsmith, C. W. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.9.1.47 · Cited by 21
Jäger, M., Riedel, M. J., Obermeier, M., Schennach-Wolff, R., Seemüller, F., Messer, T., Laux, G., Pfeiffer, H., Naber, D., Schmidt, L., et al. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.002 · Cited by 19
Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models
Yoshikawa, S., Hareyama, N., Ikeda, K., Kurokawa, T., Nakajima, M., Nakao, K., Mochizuki, H., & Ichinose, H. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.01.043 · Cited by 18
Kingdon, D. (2009) · Psychological Medicine · doi:10.1017/s0033291709990201 · Cited by 18
Risperidone, Weight Gain, and Bulimia Nervosa
Crockford, D. N., Fisher, G., & Barker, P. (1997) · The Canadian Journal of Psychiatry · doi:10.1177/070674379704200327 · Cited by 17
Brennan, J. A., Graf, R., Grauer, S. M., Navarra, R. L., Pulicicchio, C. M., Hughes, Z. A., Lin, Q., Wantuch, C., Rosenzweig-Lipson, S. J., Pruthi, F., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.157388 · Cited by 16
Jackson, M., Andree, T., Hansard, M. J., Hoffman, D., Hurtt, M., Kehne, J., Pitler, T. A., Smith, L. A., Stack, G., & Jenner, P. (2009) · Journal of neural transmission · doi:10.1007/s00702-009-0323-9 · Cited by 15
Srisurapanont, M., & Maneeton, N. (1999) · PubMed · Cited by 14
Are Second Generation Antipsychotics a Distinct Class?
Bonham, C. A., & Abbott, C. (2008) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000327312.04153.da · Cited by 14
The audacity of proteomics: a chance to overcome current challenges in schizophrenia research
Baloyianni, N. V., & Tsangaris, G. T. (2009) · Expert Review of Proteomics · doi:10.1586/epr.09.85 · Cited by 12
Geddes, J. R., Freemantle, N., Harrison, P. J., & Bebbington, P. (2006) · Cited by 12
Potential microbial origins of schizophrenia and their treatments
Fatemi, S. H. (2009) · Drugs of today · doi:10.1358/dot.2009.045.004.1353924 · Cited by 11
Use of biomarkers in the discovery of novel anti-schizophrenia drugs
Mikkelsen, J. D., Thomsen, M. S., Hansen, H. H., & Lichota, J. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.12.004 · Cited by 11
Evolution of Antipsychotic Intervention in the Schizophrenic Psychosis
Garver, D. L. (2006) · Current Drug Targets · doi:10.2174/138945006778226543 · Cited by 9
Drug Discovery in Psychiatric Illness: Mining for Gold
Elmer, G. I., & Kafkafi, N. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn194 · Cited by 8
Cognitive Behavior Therapy for Schizophrenia
Turkington, D., Kingdon, D., & Weiden, P. J. (2008) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.6.2.foc257 · Cited by 3
Chen, H., & Tandon, R. (2009) · Psychopharm Review · doi:10.1097/01.idt.0000360999.60168.a4 · Cited by 3
Self-citationNew generation versus conventional antipsychotics
Leucht, S., Wahlbeck, K., Engel, R. R., Hamann, J., & Kissling, W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14036-6 · Cited by 2
Cited by
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O'Donovan, M., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,124
Schmidt, S. J., Mueller, D. R., & Roder, V. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr079 · Cited by 461
Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies
van Kesteren, C. F. M. G., Gremmels, H., de Witte, L. D., Hol, E. M., Van Gool, A. R., Falkai, P. G., Kahn, R. S., & Sommer, I. E. C. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.4 · Cited by 368
Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
Divac, N., Prostran, M., Jakovcevski, I., & Cerovac, N. (2014) · BioMed Research International · doi:10.1155/2014/656370 · Cited by 327
Metadata
- Authors
- Tandon, R., Nasrallah, H. A., & Keshavan, M. S.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 122
- Issue
- 1-3
- Pages
- 1-23
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2139078690
- Cited by
- 385
- References
- 323
- FWCI
- 20.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.